Long-term endocrine and reproductive outcomes in female adolescent and young adult survivors after hematopoietic stem cell transplantation for hematological malignancies during childhood or adolescence
6 affiliations
- 1Division of Gynecology, Poznan University of Medical Sciences
- 2Doctoral School, Poznan University of Medical Sciences
- 3Department of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznan University of Medical Sciences
- 4Division of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences
- 5Department of Pediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences
- 6Division of Gynecology, Unit of Pediatric and Adolescent Gynecology, Poznan University of Medical Sciences
Abstract
Background: Cancer treatment during childhood and adolescence, particularly hematopoietic stem cell transplantation (HSCT), may adversely affect long-term reproductive and endocrine health in female adolescent and young adult (AYA) survivors, leading to premature ovarian insufficiency (POI), which may be associated with impaired pubertal development, low bone mass, and reproductive complications.
Methods: This study included 34 female survivors treated with HSCT for hematological malignancies during childhood or adolescence (median age 10.8 years). The median follow-up from HSCT to the last gynecological assessment was 8.5 years. Hormonal assessment, pelvic ultrasound, and bone mineral density (BMD) evaluation were performed. Patients were classified as having normal ovarian function, transient ovarian insufficiency (TOI), or persistent POI.
Results: At the last follow-up, normal ovarian function was observed in 15 patients (44.1%), TOI in 7 (20.6%), and persistent POI in 12 (35.3%). Patients with normal ovarian function were significantly older at HSCT (p = 0.0432), whereas premenarchal status was associated with impaired ovarian outcome (p = 0.0066). In multivariable analysis including cyclophosphamide equivalent dose (CED), radiotherapy, and menarchal status at HSCT, postmenarchal status was associated with markedly lower odds of ovarian insufficiency (adjusted OR 0.056, 95% CI 0.005–0.566; p = 0.0147). All postmenarchal patients received GnRHa, precluding separation of the effects of menarchal status and GnRHa exposure; GnRHa-treated survivors had higher AMH concentrations (p =0.0032). AMH and FSH concentrations differed significantly between groups (both p < 0.01). Uterine and mean ovarian volumes, antral follicle count (AFC), and BMD were significantly lower in patients with TOI and POI (all p < 0.05). Radiotherapy exposure was associated with both lower uterine and ovarian volumes, while puberty induction was also associated with lower uterine volume (all p <0.05). Two patients diagnosed with POI achieved spontaneous pregnancies during follow-up, one resulting in a live birth.
Conclusions: Ovarian dysfunction is highly prevalent after childhood HSCT, although partial recovery of ovarian function may occur even in patients with a diagnosis of POI. Persistent POI is associated with impaired uterine development and lower BMD despite ongoing hormone replacement therapy, underscoring the need for timely and long-lasting individualized endocrine and reproductive care in AYA survivors.
Related
- Increased Susceptibility to Long-Term Complications in Leukemia Survivors Who Received Hematopoietic Stem Cell Transplantation During Adolescence
- The perceptions of hematopoietic stem cell transplantation decision-making in patients with hematologic malignancies: a qualitative systematic review.
- Vaccination of patients with hematological malignancies: barriers and strategies to improve uptake
- Correlates of Caregiver Burden Among Informal Caregivers of Patients With Hematological Malignancies: The Roles of Coping, Resilience, and Perceived Social Support
- Social Inequalities, Geographical Accessibility to Care, and Excess Mortality for Patients With Hematological Malignancies in France: Results From French Cancer Registries
BibTeX
@article{zajaczkowska2026longterm,
title = {{Long-term endocrine and reproductive outcomes in female adolescent and young adult survivors after hematopoietic stem cell transplantation for hematological malignancies during childhood or adolescence}},
author = {Weronika Zajączkowska and Katarzyna Derwich and Cezary Miedziarek and Agnieszka Sobkowiak-Sobierajska and Zofia Kolesińska and Maria Buda and Witold Kędzia and Karina Kapczuk},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1921689},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1921689/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Long-term endocrine and reproductive outcomes in female adolescent and young adult survivors after hematopoietic stem cell transplantation for hematological malignancies during childhood or adolescence
AU - Weronika Zajączkowska
AU - Katarzyna Derwich
AU - Cezary Miedziarek
AU - Agnieszka Sobkowiak-Sobierajska
AU - Zofia Kolesińska
AU - Maria Buda
AU - Witold Kędzia
AU - Karina Kapczuk
PY - 2026
DA - 2026/10/15
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1921689
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1921689/full
AB - Background: Cancer treatment during childhood and adolescence, particularly hematopoietic stem cell transplantation (HSCT), may adversely affect long-term reproductive and endocrine health in female adolescent and young adult (AYA) survivors, leading to premature ovarian insufficiency (POI), which may be associated with impaired pubertal development, low bone mass, and reproductive complications. Methods: This study included 34 female survivors treated with HSCT for hematological malignancies during childhood or adolescence (median age 10.8 years). The median follow-up from HSCT to the last gynecological assessment was 8.5 years. Hormonal assessment, pelvic ultrasound, and bone mineral density (BMD) evaluation were performed. Patients were classified as having normal ovarian function, transient ovarian insufficiency (TOI), or persistent POI. Results: At the last follow-up, normal ovarian function was observed in 15 patients (44.1%), TOI in 7 (20.6%), and persistent POI in 12 (35.3%). Patients with normal ovarian function were significantly older at HSCT (p = 0.0432), whereas premenarchal status was associated with impaired ovarian outcome (p = 0.0066). In multivariable analysis including cyclophosphamide equivalent dose (CED), radiotherapy, and menarchal status at HSCT, postmenarchal status was associated with markedly lower odds of ovarian insufficiency (adjusted OR 0.056, 95% CI 0.005–0.566; p = 0.0147). All postmenarchal patients received GnRHa, precluding separation of the effects of menarchal status and GnRHa exposure; GnRHa-treated survivors had higher AMH concentrations (p =0.0032). AMH and FSH concentrations differed significantly between groups (both p < 0.01). Uterine and mean ovarian volumes, antral follicle count (AFC), and BMD were significantly lower in patients with TOI and POI (all p < 0.05). Radiotherapy exposure was associated with both lower uterine and ovarian volumes, while puberty induction was also associated with lower uterine volume (all p <0.05). Two patients diagnosed with POI achieved spontaneous pregnancies during follow-up, one resulting in a live birth. Conclusions: Ovarian dysfunction is highly prevalent after childhood HSCT, although partial recovery of ovarian function may occur even in patients with a diagnosis of POI. Persistent POI is associated with impaired uterine development and lower BMD despite ongoing hormone replacement therapy, underscoring the need for timely and long-lasting individualized endocrine and reproductive care in AYA survivors.
SN - 1664-2392
ER -